Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulmonx has the GF Score of 49, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Pulmonx
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Pulmonx (FRA:4NI) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Pulmonx GF Score Related Terms
FRA:4NI vs MDAI, QTI, COCH: GF Score Comparison
For the Medical Devices subindustry, Pulmonx's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulmonx GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's GF Score distribution charts can be found below:
* The bar in red indicates where Pulmonx's GF Score falls into.
Pulmonx (FRA:4NI) has a GF Score of 49 as of Jul. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pulmonx and its competitors. This is 40% above median its historical median of 35.00. Over the past decade, Pulmonx's GF Score has ranged from 13.00 to 71.00.
Is Pulmonx's GF Score too high?
Pulmonx's current GF Score of 49 is 40% above median its 10-year median of 35.00. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 71.00. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's GF Score compare to MDAI and QTI?
Pulmonx's GF Score of 49 can be compared against companies in the Medical Devices & Instruments industry. Historically, Pulmonx's own GF Score has ranged from 13.00 to 71.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pulmonx and its competitors. Pulmonx's current GF Score is 49, which is 40% above median its own 10-year median of 35.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (FRA:4NI) is currently considered Possible Value Trap. The stock's GF Value™ is €6.42, compared to a current price of €1.30 — trading 79.8% below its estimated fair value. The current GF Score is 49, which is 40% above median its 10-year median of 35.00. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Pulmonx (FRA:4NI), the current GF Score is 49 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulmonx (FRA:4NI) Overvalued in 2026?
Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued.
The current stock price of €1.30 is trading 79.8% below its estimated GF Value™ of €6.42.
GuruFocus considers Pulmonx to be Possible Value Trap.
Key valuation signals for FRA:4NI:
GF Score: 49 (40% above median its 10-year median of 35.00)
GF Value™: €6.42 vs. price of €1.30 (79.8% below fair value)
No single metric tells the full story. See the FRA:4NI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score
Get the complete analysis for FRA:4NI
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4NI has been successfully added to your 
